Here we discuss the use of postoperative cognitive decline (POCD), which is hypothesised to have a neuroinflammatory basis, as an acute indication to demonstrate the efficacy of novel neuroinflammatory drugs.

Here we provide a brief review of the history behind latent inhibition and the limitations of existing human paradigms, before discussing a more recent latent inhibition task modification and its potential as a biomarker for schizophrenia.

Will an expansion in the use of effective digital biomarkers help improve the productivity of drug development in neuroscience? Ask Dr J. Mark Treherne, Dr Jenny Barnett and Dr Paula Moran.